Last reviewed · How we verify

IRCCS Burlo Garofolo — Portfolio Competitive Intelligence Brief

IRCCS Burlo Garofolo pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Hypertonic solution (NaCl 3%) Hypertonic solution (NaCl 3%) phase 3 Osmotic diuretic / Hypertonic solution Neurology / Critical Care
Isotonic solution (NaCl 0.9%) Isotonic solution (NaCl 0.9%) phase 3 Crystalloid fluid / Electrolyte solution Critical Care / Fluid Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Centre Hospitalier Universitaire de Nice · 1 shared drug class
  2. Daniel Hägi-Pedersen · 1 shared drug class
  3. Helse Nord-Trøndelag HF · 1 shared drug class
  4. Hennepin Healthcare Research Institute · 1 shared drug class
  5. Meshalkin Research Institute of Pathology of Circulation · 1 shared drug class
  6. Ministry of Health, Spain · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for IRCCS Burlo Garofolo:

Cite this brief

Drug Landscape (2026). IRCCS Burlo Garofolo — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/irccs-burlo-garofolo. Accessed 2026-05-17.

Related